PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Cash & equivalents declining -9.09% while AVXL's grows 0.88%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Below half of AVXL's 0.88%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Above 1.5x AVXL's -15.71%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-10.41%
≥ 1.5x AVXL's -0.86%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-5.27%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Higher Long-Term Investments Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
≥ 1.5x AVXL's -0.86%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-5.64%
Less than half of AVXL's -33.89%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-5.23%
Less than half of AVXL's -21.15%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Less than half of AVXL's -12.27%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Less than half of AVXL's -21.15%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
Similar yoy to AVXL's -4.15%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
Below half AVXL's 1.09%. Michael Burry sees potential underperformance in building shareholder capital.
-10.20%
≥ 1.5x AVXL's -0.86%. David Dodd sees faster overall balance sheet growth than competitor.
0.98%
Higher Total Investments Growth compared to AVXL's zero value, indicating better performance.
-5.39%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
9.19%
Less than half of AVXL's -0.88%. David Dodd sees better deleveraging or stronger cash buildup than competitor.